2025
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
Luskin M, Murakami M, Keating J, Flamand Y, Winer E, Garcia J, Stahl M, Stone R, Wadleigh M, Jaeckle S, Hagopian E, Weinstock D, Liegel J, McMasters M, Wang E, Stock W, DeAngelo D. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia. Blood 2025, 145: 577-589. PMID: 39374521, DOI: 10.1182/blood.2024025800.Peer-Reviewed Original ResearchConceptsAcute leukemiaPhiladelphia chromosome-positive acute leukemiaRecommended phase 2 dosePh+ acute lymphoblastic leukemiaHematopoietic stem cell transplantationDe novo ALLHematologic remission rateLymphoid blast crisisMaximum tolerated doseStem cell transplantationPhase 1 studyChronic myeloid leukemiaMulticolor flow cytometryAcute lymphoblastic leukemiaVaso-occlusive eventsCytogenetic remissionBlast crisisSymptomatic pancreatitisTolerated doseRemission ratePh+ ALLCell transplantationMedian ageEnzyme elevationLymphoblastic leukemia
2023
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Badar T, Atallah E, Shallis R, Saliba A, Patel A, Bewersdorf J, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg A, Abaza Y, Murthy G, Kota V, Litzow M. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia 2023, 37: 799-806. PMID: 36807649, DOI: 10.1038/s41375-023-01847-7.Peer-Reviewed Original ResearchConceptsEvent-free survivalAllo-HSCTOverall survivalChronic GVHDAllogeneic hematopoietic stem cell transplantAllogeneic stem cell transplantationMedian event-free survivalHematopoietic stem cell transplantAcute myeloid leukemia patientsMedian overall survivalPost allo-HSCTReduced intensity conditioningStem cell transplantStem cell transplantationLong-term outcomesMyeloid leukemia patientsMulti-center studyAcute graftComplete remissionHost diseaseSalvage therapyComplex cytogeneticsMyeloablative conditioningMedian ageCell transplant
2022
Racial disparities in patients with TP53 mutated acute myeloid leukemia.
Badar T, Litzow M, Shallis R, Stahl M, Bewersdorf J, Saliba A, de Camargo Correia G, Patel A, Abaza Y, Murthy S, Duvall A, Burkart M, Al-Kali A, Palmisiano N, Dinner S, Goldberg A, Atallah E. Racial disparities in patients with TP53 mutated acute myeloid leukemia. Journal Of Clinical Oncology 2022, 40: e19007-e19007. DOI: 10.1200/jco.2022.40.16_suppl.e19007.Peer-Reviewed Original ResearchAcute myeloid leukemiaBlacks/HispanicsSupportive careClinical outcomesMyeloid leukemiaTherapy-related acute myeloid leukemiaMedian event-free survivalAllogeneic stem cell transplantationRacial disparitiesCurative-intent therapySubset of ptsEvent-free survivalHigh-risk diseaseStem cell transplantationHigher proportionHigh rateRace/ethnicityAML ptsBaseline characteristicsComplete remissionCPX-351Free survivalComplex cytogeneticsMedian agePoor OS
2020
Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative
Pollyea D, Stahl M, Talati C, Asghari H, Lai C, Abedin S, Zeidner J, Muluneh B, Xavier M, Edwards W, Wolach O, Moshe Y, Lavie D, Zuckerman T, Choi M, Bui C, Svensson A, Kye S, Burne R, Guerin A, Ma E, Montez M, Goldberg A. Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative. Blood 2020, 136: 26-28. DOI: 10.1182/blood-2020-134789.Peer-Reviewed Original ResearchAcute myeloid leukemiaCurrent equity holderEntity's Board of DirectorsEmployees of Analysis GroupEvent-free survivalECOG performance statusOverall survivalControl cohortHigh-intensity therapyELN classificationFavorable-riskMedian agePerformance statusFLT3-ITDNewly diagnosed acute myeloid leukemia patientsDe novo acute myeloid leukemiaDaiichi Sankyo: ConsultancyHigh-intensity chemotherapy regimensSanofi GenzymeAcute myeloid leukemia patientsMulticenter chart review studyND AML patientsSubgroups of ptsLow-dose cytarabineAccelerated FDA approval
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply